Romosozumab improves lumbar spine BMD and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial

• Jacques P. Brown,
• Arkadi Chines,
• Roland Chapurlat,
• Joseph Foldes,
• Xavier Nogues,
• Roberto Civitelli,
• Tobias De Villiers,
• Fabio Massari,
• Cristiano Zerbini,
• Wenjing Yang,
• Chris Recknor,
• Cesar Libanati

Affiliations

Jacques P. Brown

Laval University, Quebec City, Canada

Arkadi Chines

Amgen Inc., Thousand Oaks, United States

Roland Chapurlat

INSERM UMR 1033, University of Lyon, Lyon, France

Joseph Foldes

Hadassah Hebrew University Medical Center, Jerusalem, Israel

Xavier Nogues

IMIM Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain

Roberto Civitelli

Washington University School of Medicine, St. Louis, United States

Tobias De Villiers

Stellenbosch University, Stellenbosch, South Africa

Fabio Massari

Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina

Cristiano Zerbini

Centro Paulista de Investigação Clinica, São Paulo, Brazil

Wenjing Yang

Amgen Inc., Thousand Oaks, United States

Chris Recknor

United Osteoporosis Centers, Gainesville, United States

Cesar Libanati

UCB Pharma, Brussels, Belgium; Corresponding author.